

PROF MAX ALLAN SCHWARZ AM

ONCOLOGIST

MBBS (HONS) FRACP FACP FACHPM

QUALIFICATIONS

MB., BS. Division II A Honours Monash University (1969)
Honours: Medicine, Surgery, Pathology, Microbiology, Paediatrics, Obstetrics and Gynaecology
M.R.A.C.P Member of the Royal Australasian College of Physicians (March 1973)
(F.R.A.C.P.) Fellow of the Royal Australasian College of Physicians (May 1976)
Member of the American College of Physicians (April 1977)
(F.A.C.P.) Fellow of the American College of Physicians (November 1981)
(FACHPM) Foundation Fellow of the Australasian Chapter of Palliative Medicine, (July 2000)

ACCREDITATIONS

SUB-SPECIALTIES

CURRENT POSITIONS

PROFESSIONAL EXPERIENCE

Junior Resident Medical Officer (1970-1971)
Alfred Hospital, Melbourne

Senior Resident Medical Officer (1971-1972)
Alfred Hospital, Melbourne, Australia

Medical Registrar (1972-1973)
Alfred Hospital

Senior Medical Registrar and Teaching Fellow (1973-1974)
Monash University, Department of Medicine
Prince Henry's Hospital, Melbourne, Australia

Haematology Registrar (1973-1974)
Prince Henry's Hospital

**Assistant Physician and National Health and Medical Research
Council Fellow (January 1974-June 1975)**
Monash University, Department of Medicine,
Alfred Hospital, Melbourne, Australia

Fellow, Department of Developmental Therapeutics, M.D. (1975-1976)
Anderson Hospital & Tumour Institute, University of Texas
System Cancer Centre, Houston, Texas, U.S.A.

Faculty Associate, Department of Developmental Therapeutics, M.D. (1976-1977)
Anderson Hospital and Tumour Institute,
University of Texas System Cancer Centre, Houston, Texas, U.S.A

Assistant Professor, Department of Developmental Therapeutics, M.D. (1977)
Anderson Hospital and Tumour Institute
University of Texas System Cancer Centre, Houston, Texas, U.S.A.

Consultant Physician and Medical Oncologist (1977-1989)
Alfred Hospital, Melbourne, Australia

Senior Lecturer (part-time) (1977-1991)
Monash University, Department of Medicine, Alfred Hospital, Melbourne

Consultant Medical Oncologist (1977)
Royal Southern Memorial Hospital (Caulfield General Med. Centre), Melbourne,

Co-ordinator of Medical Oncology (1986-1989)
Alfred Hospital, Melbourne

Head, Medical Oncology Unit (1989)
Alfred Hospital, Melbourne

Associate Professor (Clinical) Monash University (1991-2009)
Department of Medicine, Alfred Hospital, Melbourne

Consultant Medical Oncologist (1977)
Cabrini Hospital and Medical Centre, Melbourne

Consultant Medical Oncologist (1999)
Bethlehem Hospital, Melbourne,

Adjunct Professor, Monash University, Department of Medicine (2009)
Central Clinical School, Faculty of Medicine, Nursing and Health Sciences

BIOGRAPHY

LOCATION

ADDITIONAL INFO

AWARDS

Member in the General Division of the Order of Australia: AM, June 2016

SCHOLARSHIPS:

1. National Health and Medical Research Council Scholarship, 1974-1975.
2. Fulbright-Hays Scholarship 1975, 1976, 1977.
3. Searle - Post Graduate Federation of Medicine Clinical Pharmacology Travelling Fellowship, 1978
4. Peter Grant Hay Memorial Research Fellowship, 1981, 1982.

MEMBER OF SOCIETIES:

A. Current:

- (i) Australian Medical Association
- (ii) Clinical Oncology Society of Australia
- (iii) Medical Oncology Group of Australia (Foundation Member)
- (iv) American Society of Clinical Oncology
- (v) American Association for Cancer Research

B. Past:

- (i) Haematology Society of Australia
 - (ii) Australian Society of Medical Research
 - (iii) Australian Association of Consultant Physicians
 - (iv) International Society for Supportive Care in Oncology
2. Executive Committee of Australian Society of Medical Oncology, 1978 - 1987.

PROFESSIONAL ACTIVITIES:

- Anti-Cancer Council of Victoria:
 - (i) Member of Breast Cancer Study Groups, 1977 -

- (ii) Victorian Co-Operative Oncology Group, 1977 -
- (iii) Medical and Scientific Advisory Committee, 1986 - 2010
- (i) Federal Councillor - Royal Australasian College of Physicians, May 1978 - May 1979
- (ii) Chairman, Specialist Advisory Committee in Medical Oncology, Royal Australasian College of Physicians, November 1980 - February, 1986
- (iii) Royal Australasian College of Physicians. Part I Fellowship Co-Opted Clinical Examiner, 1987 -
- (iv) Reviewer for The Australian and New Zealand Journal of Medicine, 1983 -
- (v) Reviewer for the Australian and New Zealand Journal of Surgery, 1996 -
- (vi) Reviewer for the Medical Journal of Australia, 1997 -
- (vii) Reviewer for the Australasian Journal of Dermatology, 1997 -
- (viii) Reviewer For Medicine Today, 2005 -
- Member of The National Health and Medical Research Council Panel of Independent Assessors, 1987 -
- Assessor for The National Occupational Health and Safety Commission Research Grants Scheme, 1988 -
- National Cancer Assessors Panel of Research Grants for:
 - (i) Anti Cancer Foundation of the Universities of South Australia, 1989-
 - (ii) Anti Cancer Council of New South Wales, 1989 -
 - (iii) Anti Cancer Council of Queensland, 1989 -
 - (iv) Anti Cancer Council of Tasmania, 1989 -
 - (v) Anti Cancer Council of Victoria, 1986 -
- Australian Cancer Society Oncology Education Committee 1999-2016
- Victorian Government Medical Panels, 2007 -

BIBLIOGRAPHY:

A. PAPERS

1. Tauro G.P., Danks D.M., Rowe P.B., Van der Weyden M.B., Schwarz M.A., Collins V.L. and Neal B.W. : Dihydrofolate Reductase Deficiency Causing Megaloblastic Anemia in Two Families. New England Journal of Medicine 294: 446-470, 1976.
2. **Schwarz M.A.**, Firkin B.G.: Chloramphenicol - A Possible Role in the Treatment of Leukaemia. Medical Journal of Australia 1: 687-690, 1976.
3. Spitzer G., Schwarz M.A., Dicke K.A., Trujillo J.M., McCredie K.B. : Significance of PHA Induced Clonogenic Cells in Chronic Myeloid Leukemia and Early Acute Myeloid Leukemia. Blood Cells 2: 149-159, 1976.
4. **Schwarz M.A.**: Immunotherapy of Leukemia and Lymphoma. Cancer Bulletin 28: 18-22, #3, 1976.
5. Hortobagyi G.M., Gutterman J.U., Blumenschein G.R., Buzdar A., Burgess M.A., Richman S.P., Tashima C.K., **Schwarz M.A.** and Hersh E.M. : Chemoimmunotherapy of Advanced Breast Cancer with BCG. In: Recent

- Results in Cancer Research Volume 62, G. Mathe Editor, Springer-Verlag New York, 1977, pp 143-150.
6. **Schwarz M.A.**, Gutterman J.U., Hersh E.M., Richman S.P., Mavligit G.M.: Immunotherapy and Chemoimmunotherapy of Malignant Disease with BCG and Nonviable Mycobacterial Fractions. World Journal of Surgery, 1, 555-583, 1977.
 7. Gutterman J.U., Hersh E.M., Mavligit G.M., Burgess M.A., Richman S.P., **Schwarz M.A.**, Rodriguez V. and Valdivieso M. : Chemoimmunotherapy of Disseminated Malignant Melanoma with Bacillus Calmette Guerin: 54-Month Follow-Up. In: Immunotherapy of Cancer. Present Status of Trials in Man. R. Terry, D. Windherst Editors, New York, Raven Press, 1978, pp. 103-112.
 8. Hortobagyi G.M., Gutterman J.U., Blumenschein G.R., Buzdar A., Burgess M.A., Richman S.P., Tashima C.K., Schwarz M.A. and Hersh E.M.: Chemoimmunotherapy of Advanced Breast Cancer with BCG. In: Immunotherapy of Cancer: Present Status of Trials in Man. R. Terry, D. Windherst Editors, New York, Raven Press, 1978 pp 655-662.
 9. Gutterman J.U., Mavligit G.M., **Schwarz M.A.** and Hersh E.M.: Immunotherapy of Human Solid Tumours: Principles of Development. In: Immunological Aspects of Cancer. Edited by J.E. Castro. MTP Press Limited, London, England, 1978, pp 415-470.
 10. Maroun J.A., Quesada J.R., Hersh E.M., Gutterman J.U., Richman S., Schwarz M.A. and Parker N.: Phase I Toxicity Study of Methanol-Extracted Residue of Bacillus Calmette-Guerin by the I.V. Route. Cancer Treat Rep. 63: 1781-1786, 1979.
 11. Snyder R.D. and Schwarz M.A.: Clinical Trials in Cancer Medicine. Australian Family Physician 9, 23-26, 1980.
 12. **Schwarz M.A.**, Gutterman J.U., Burgess M.A., Heilburn L.K. Murphy W.K., Bodey G.P., Stone E., Turner-Chism V., and Hersh E.M.: Chemoimmunotherapy of Disseminated Malignant Melanoma with DTIC-BCG, Transfer Factor ± Melphalan, Cancer 45: 2506-2515, 1980.
 13. Russell I., Schwarz M.A., Forbes J.F., Kitchen P.R.B., Bennett R.C., Guli E., Reed R., Funder J. (Anti-Cancer Council of Victoria, Australia: Ludwig Breast Cancer Study Group): Principles of Clinical Trials In: Recent Results in Cancer Research, Volume 71, B. Henningsen, F. Linder, C. Steichele Editors, Springer-Verlag, New York 1980. pp 190-197.
 14. Pihl E., Jansson B., Schwarz M.A., Malahy M.A., Smith Jr., J.L., Gutterman J.U., and Hersh E.M.: Germinal Centre Hyperplasia: An Unfavourable Immune Response in Recurrent Malignant Melanoma. Pathology 14: 13-16, 1982.
 15. Olver I.N. and Schwarz M.A.: Use of Dimethyl Sulfoxide in Limiting Tissue Damage Caused by Extravasation of Doxorubicin. Cancer Treatment Reports. Volume 67, Number 4, 407-408, April 1983.
 16. Olver I.N., Schwarz M.A., Westmore D. and Masterton J.P.: Complete Remission in Extragonadal Seminoma Primarily Treated with Chemotherapy and Restaging by Retroperitoneal Nodal Dissection. Aust. N.Z. J. Surg. 53, 277-280. 1983.
 17. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Toxic Effects of Early Adjuvant Chemotherapy for Breast Cancer. Lancet 2: 542-544, 1983.

18. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: for Anti-Cancer Council of Victoria): Adjuvant Therapy for Post Menopausal Women with Operable Breast Cancer. Part 1 - A Randomized Trial of Chemo-Endocrine Versus Endocrine Therapy Versus Mastectomy Alone. In: Adjuvant Therapy of Cancer IV: Stephen E. Jones, Sydney E. Salmon. Editors, Grune & Stratton, New York, 1984, pp 379-391.
19. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: for Anti-Cancer Council of Victoria): Adjuvant Endocrine Therapy for Post Menopausal Women with Operable Breast Cancer. Part II - Randomized Trials Comparing Endocrine Therapy with Surgery Alone. In: Adjuvant Therapy of Cancer IV: Stephen E. Jones, Sydney E. Salmon. Editors, Grune & Stratton, New York, 1984, pp 393-404.
20. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: for Anti-Cancer Council of Victoria): Randomized Trial of Chemo-Endocrine Therapy, Endocrine Therapy and Mastectomy Alone in Post Menopausal Patients with Operable Breast Cancer and Axillary Node Metastasis. Lancet 1: 1256-1260, 1984.
21. Ludwig Breast Cancer Trial LBCS III (Gelber R., Collins J., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Chemo and Endocrine Adjuvant Treatment in Post Menopausal Patients. In: Recent Results in Cancer Research, Adjuvant Chemotherapy of Breast Cancer, Vol. 96, pp 102-109, Editor, H.J. Senn, Springer Verlag, Berlin and Heidelberg, 1984.
22. Ludwig Breast Cancer Trial LBCS III and IV (Goldhirsch A., Collins J., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Endocrine Treatment in Post Menopausal Patients. In: Recent Results in Cancer Research, Adjuvant Chemotherapy of Breast Cancer, Vol. 96, pp 204-209, Editor, H.J. Senn, Springer Verlag, Berlin and Heidelberg, 1984.
23. Haines I.E., **Schwarz M.A.**, Hurley R.A., and Rundle H.M.P. : Recurrent Nasopharyngeal Carcinoma - Two Long Term Disease-Free Remissions with Non-Cisplatinum Based Combination Chemotherapy. Aust. N.Z. J. Surg. 55, 153-156, 1985.
24. Haines I.E., **Schwarz M.A.**, Westmore D.D., and Sutherland R.C.: Rhabdomyosarcoma in a Patient Treated for Metastatic Germ Cell Tumour of the Testis Containing Teratoma. Aust. N.Z. J. Surg. 55, 141-143, 1985.
25. Haines I.E., **Schwarz M.A.**, Sinclair R.A., and Ostor A.G. : Recurrent Dysgerminoma After 33 years. Aust. N.Z. J. Obstet. Gynaecol. 25, 126-129, 1985.
26. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): A Randomized Trial of Adjuvant Combination Chemotherapy With or Without Prednisone in Premenopausal Breast Cancer Patients with Metastases in 1 to 3 Axillary Nodes. Cancer Res. 45, 4454-4459, 1985.
27. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Chemotherapy With or Without Oophorectomy in High-Risk Premenopausal Patients with Operable Breast Cancer. Journal of Clinical Oncology 3:8, 1059-1067, 1985.
28. Webster R., Hurley R., Orchard W., **Schwarz M.A.**, Snyder R.D., Sullivan J. et al: For Anti-Cancer Council of Victoria: Palliative Care for Cancer Patients.

- Medical Journal of Australia 143: 547-550, 1985.
29. Ludwig Breast Cancer Study Group (Davis B.W., Gelber R., Goldhirsch A., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Prognostic Significance of Peritumoural Vessel Invasion in Clinical Trials of Adjuvant Therapy for Breast Cancer with Axillary Lymph Node Metastasis. Human Pathology, 16:12, 1212-1218, 1985.
30. Ludwig Breast Cancer Study Group (Rudenstam C.M., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): The Ludwig Breast Cancer Studies in Post Menopausal Patients with Axillary Node Metastasis. Rev. Endocrine-Related Cancer 17: 25-32, 1985.
31. Ludwig Breast Cancer Study Group (Goldhirsch A., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Treatment in Operable Breast Cancer. J. Steroid Biochem. 23: 1155-1160, 1985.
32. Australian and New Zealand Breast Cancer Trials Group, Clinical Oncology Society of Australia: Forbes J.A., Schwarz M.A. et al : A Randomized Trial in Postmenopausal Patients with Advanced Breast Cancer Comparing Endocrine and Cytotoxic Therapy Given Sequentially or in Combination. Journal of Clinical Oncology 4:2, 186-193, 1986.
33. Ludwig Breast Cancer Study Group (Pedrazzini A., Gelber R., Isley M., Goldhirsch A., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): First Repeated Bone Scan in the Observation of Patients with Operable Breast Cancer. Journal of Clinical Oncology, 4:3, 389-394, 1986.
34. Haines I.E., and Schwarz M.A.: A Rare Opportunity To Observe Aspects of the Natural History of Untreated Hodgkin's Disease. Medical Journal of Australia, 144:12, 652-654, 1986.
35. Toner G.C., Sinclair R.A., Sutherland R.C., and Schwarz M.A.: Composite Lymphoma. American Journal of Clinical Pathology, 86:3, 375-378, 1986.
36. Pakes W.L., Muller H.K., Schwarz M.A. and Marks R.: Langerhans Cells: A Reduction in Numbers and Their Reappearance Following Steroid and Cytotoxic Therapy in Humans. Clinical and Experimental Dermatology, 11: 450-459, 1986.
37. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Treatment for Early Breast Cancer: The Ludwig Breast Cancer Studies. N.C.I. Monographs 1: 55-70, 1986.
38. Ludwig Breast Cancer Study Group (Gelber R.D., Goldhirsch A., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): A New Endpoint for the Assessment of Adjuvant Therapy in Post Menopausal Women with Operable Breast Cancer. Journal of Clinical Oncology, 4:12, 1772-1779, 1986.
39. Ludwig Breast Cancer Study Group (Davis B.W., Gelber R.D., Goldhirsch A., Hartmann W.H., Reed R., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Prognostic Significance of Tumor Grade in Clinical Trials of Adjuvant Therapy for Breast Cancer with Axillary Lymph Node Metastasis. Cancer 58: 2662-2670, 1986.
40. The Ludwig Breast Cancer Studies: Adjuvant Therapy for Early Breast Cancer. (Cavalli F., Goldhirsch A., Gelber R., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): In Estrogen-Antiestrogen Action and Breast Cancer Therapy. pp 459-469, Editor V. Craig Jordan, The University

- of Wisconsin Press, 1986.
41. Snyder R., Bishop J., Brodie G., Burns W., Coates A., Levi J., Raghavan D., **Schwarz M.A.**, Tattersall M., Thomson D., Woods R., and Ziogas V.: Phase I Study of Epirubicin Given on a Weekly Schedule. *Cancer Treatment Reports* Vol. 71, No. 3. 273-276, March 1987.
 42. Toner G.C., Holmes R., Kennedy J.T., Schwarz M.A.: Lethal Skin Cancers in Hairy Cell Leukaemia. *European Journal of Haematology* 39: 82-85, 1987.
 43. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Therapy for Breast Cancer: The Ludwig Breast Cancer Trials 1987. In: *Adjuvant Therapy of Cancer V: Sydney E. Salmon, Editor. Grune & Stratton, Orlando 1987 pp. 297-309.*
 44. Ludwig Breast Cancer Study Group (Gelber R.D., Goldhirsch A., Castiglione M., Price K., Isley M., Coates A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Time Without Symptoms and Toxicity (TWIST): A Quality-of-Life-Oriented Endpoint to Evaluate Adjuvant Therapy. In: *Adjuvant Therapy of Cancer V: Sydney E. Salmon. Editor, Grune & Stratton, Orlando 1987. pp. 455-465.*
 45. Snow R.M., Westmore D.D., Brown R.B., and Schwarz M.A.: Extragonadal Germ Cell Tumours. *Aktuelle Urologie (European Journal of Urology): Vol. 18, No. 6, 297-298, 1987.*
 46. Ludwig Breast Cancer Study Group (Hedley D.W., Rugg C.A., Gelber R.D., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Association of DNA Index and S-Phase Fraction with Prognosis of Nodes Positive Early Breast Cancer. *Cancer Research, 47, 4729-4735, 1987.*
 47. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Relapse of Breast Cancer after Adjuvant Treatment in Premenopausal and Perimenopausal Women: Patterns and Prognoses. *Journal of Clinical Oncology, 6:1, 89-97, 1988.*
 48. Holmes R., **Schwarz M.A.**, Whiteside M.G., Firkin F.C.: Treatment of Hairy Cell Leukaemia with Increasing Doses of Recombinant Alpha A Interferon: *Aust. N.Z. J. Med, 18, 557-562, 1988.*
 49. Australasian Germ Cell Trial Group: Levi J.A., Thomson D., Sandeman T., Tattersall M., Raghavan D., Byrne M., Gill G., Harvey V., Burns I., Snyder R., Schwarz M.A. et al: A Prospective Study of Cisplatin-Based Combination Chemotherapy in Advanced Germ Cell Malignancy: Role of Maintenance and Long Term Follow-Up. *Journal of Clinical Oncology, 6:7, 1154-1160, 1988.*
 50. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Combination Adjuvant Chemotherapy for Node-Positive Breast Cancer. Inadequacy of a Single Perioperative Cycle. *New England Journal of Medicine* 319, 677-683, 1988.
 51. Ludwig Breast Cancer Study Group (Rudenstam C.M., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): On the Safety of Perioperative Adjuvant Chemotherapy with Cyclophosphamide, Methotrexate and 5-Fluorouracil in Breast Cancer. *Eur.J. Cancer Clin. Oncol. Vol. 24, No. 8, pp 1305-1308, 1988.*
 52. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collins J.,

- Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Chemohormonal Therapy of Operable Breast Cancer. Cancer Investigation 6, 558-560, 1988.
53. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast Cancer. New England Journal of Medicine 320, 491-496, 1989.
54. Toner G.C., Thomas R.L., and Schwarz M.A.: Metastatic Bone Marrow Involvement from Supraglottic Squamous Cell Carcinoma. The Journal of Laryngology and Otology 103, 225-226, 1989.
55. Toner G.C., Holmes R., Sinclair R.A., Tang S.K., Schwarz M.A.: Central Nervous System Lymphoma: Primary Lumbar Nerve Root Infiltration. Acta Haematologica 81, 44-47, 1989.
56. Australasian Germ Cell Trial Group: Raghavan D., Levi J., Thomson D., Byrne M., Harvey V., Tattersall M., Fox R., Abbott R., Burns I., Bishop J., Sandeman T., Schwarz M.A. et al: Chemotherapy of Advanced Germ Cell Tumours: Overview of Australasian Germ Cell Tumour Group Studies. In: Systemic Therapy for Genitourinary Cancers: Douglas E. Johnson, Christopher J. Logothetis and Andrew C. Von Eschenbach, Editors, Year Book Medical Publishers, Chicago 1989: Chapter 46, pp. 342-348.
57. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Simes J., Glasziou P., Coates A.S., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Costs and Benefits of Adjuvant Therapy in Breast Cancer: A Quality-Adjusted Survival Analysis. Journal of Clinical Oncology, 7:1, 36-44, 1989.
58. Toner G.C., Pike J., Schwarz M.A.: The Blood-Brain Barrier and Response of C.N.S. Metastases to Chemotherapy. Journal of Neuro-Oncology 7: 21-24, 1989.
59. Alderuccio F., Rolland J.M., Toner G.C., **Schwarz M.A.**, McCluskey J., and Toh B.H.: Autoantibodies to Neurons and to the Cytoskeleton in Small Cell Carcinoma with Paraneoplastic Sensory Neuropathy. Autoimmunity, 5:115-123, 1989.
60. Australasian Germ Cell Trial Group: Levi J., Thomson D., Bishop J., Raghavan D., Tattersall M., Byrne M., Gill G., Harvey V., Snyder R., Dalley D., Sandeman T., Schwarz M.A. et al: Dose Intensity and Outcome with Combination Chemotherapy for Germ Cell Carcinoma. European Journal Cancer Clinical Oncology, 25:7, 1073-1077, 1989.
61. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Randomized Perioperative Therapy in Operable Breast Cancer: The Ludwig Trial V. In: Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research: H.J. Senn, A. Goldhirsch, R.D. Gelber, B. Osterwalder, Editors, Springer-Verlag, Berlin, 1989, pp 43-53.
62. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Adjuvant Chemo-Endocrine Therapy or Endocrine Therapy Alone for Postmenopausal Patients: Ludwig Studies III and IV. In: Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research: H.J. Senn, A. Goldhirsch, R.D. Gelber, B. Osterwalder, Editors, Springer-Verlag,

- Berlin, 1989, pp 153-162.
63. The International Breast Cancer Study Group (Goldhirsch A., Castiglione M., Gelber R.D., Collins J., Schwarz M.A. et al.: For Anti-Cancer Council of Victoria): Late Effects of Adjuvant Oophorectomy and Chemotherapy upon Premenopausal Breast Cancer Patients. *Annals of Oncology* 1: 30-35, 1990.
 64. Australasian Germ Cell Trial Group: Levi J.A., Thomson D., Harvey V., Gill G., Raghavan D., Tattersall M., Snyder R., Burns I., Sandeman T., Byrne M., and Schwarz M.A.: Effective Salvage Chemotherapy with Etoposide, Dactinomycin, and Methotrexate in Refractory Germ Cell Cancer. *Journal of Clinical Oncology*, 8:1, 27-32, 1990.
 65. McNaughton W.M., Broughton M., Toner G.C., and Schwarz M.A.: Presentation of Malignant Pleural Mesothelioma with Cerebral Metastases. *Journal of the Royal Society of Medicine*, 83, 466-467, 1990.
 66. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): The Magnitude of Endocrine Effects of Adjuvant Chemotherapy for Premenopausal Breast Cancer Patients. *Annals of Oncology* 1: 183-188, 1990.
 67. The International Breast Cancer Study Group (Castiglione M., Gelber R.D., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria) Adjuvant Systemic Therapy for Breast Cancer in the Elderly: Competing Causes of Mortality. *Journal of Clinical Oncology*, 8:3, 519-526, 1990.
 68. The International Breast Cancer Study Group (Bettelheim R., Neville A.M., Davis B., Hartmann W.H., Goldhirsch A., Reed R., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Prognostic Importance of Occult Axillary Lymph Node. Micrometastases from Breast Cancers. *Lancet*, 335, 1565-1568, 1990.
 69. The International Breast Cancer Study Group (Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam C.M., Senn H.J., Lindtner J., Brunner Y.C., Cavalli F., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Adjuvant Systemic Therapy in Elderly Patients with Node Positive Breast Cancer. In: *Adjuvant Therapy of Cancer VI: Sydney E. Salmon, Editor, W.B. Saunders, Philadelphia, 1990. pp. 310-318.*
 70. The International Breast Cancer Study Group (Castiglione M., Weber W., Gelber R., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Family History and Prognosis of Patients with Node Positive Breast Cancer Treated with Adjuvant Therapy. In: *Hereditary Cancer and Preventive Surgery. Weber W., Laffer U.T., Dürig M., Editors, Karger, Basel, 1990. pp. 105-114.*
 71. The International Breast Cancer Study Group (Gelber R.D., Goldhirsch A., Cavalli F., Collins J., Snyder R., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Quality-of-Life Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. *Annals of Internal Medicine* 114:8, 621-628, 1991.
 72. The International Breast Cancer Study Group (Castiglione M., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Is the Adjuvant Therapy for Node-Negative Breast Cancer Necessary? *Diagnostic Oncology*, 1, 98-101, 1991.
 73. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D.,

- Castiglione M., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Adjuvant Therapy of Breast Cancer. European Journal of Cancer, 27:3, 389-399, 1991.
74. Cosolo W., **Schwarz M.A.**, Christophidis N., and Zalcborg J.R: Interaction of Cisplatin with other Cytotoxics and Non-Steroidal Anti-Inflammatory Drugs. Anti-Cancer Drugs 2: 169-174, 1991.
 75. The International Breast Cancer Study Group. (Neville A.M., Bettelheim R., Gelber R.D., Reed R., Collins J., Snyder R.D. & Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Factors Predicting Treatment Responsiveness and Prognosis in Node Negative Breast Cancer. J Clin Onc 10:5, 696-705, 1992.
 76. The International Breast Cancer Study Group. (Gusterson B.A., Gelber R.D., Goldhirsch A., Reed R, Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Prognostic Importance of C-erbB-2 Expression in Breast Cancer. J Clin Onc 10: 7, 1049-1056, 1992.
 77. The International Breast Cancer Study Group. (Gelber R.D., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Reporting and Interpreting Adjuvant Therapy Clinical Trials. J Nat Canc Inst Monographs. 11: 59-69, 1992.
 78. The International Breast Cancer Study Group. (Goldhirsch A., Castiglione M., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). A Single Perioperative Adjuvant Chemotherapy Course For Node-Negative Breast Cancer: Five-Year Results of Trial V. J Nat Canc Inst Monographs 11: 89-96, 1992.
 79. The International Breast Cancer Study Group. (Gelber R.D., Goldhirsch A., Hürny C., Bernhard J., Simes R.J., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Quality of Life in Clinical Trials of Adjuvant Therapies. J Nat Canc Inst Monographs 11: 127-135, 1992.
 80. The International Breast Cancer Study Group. (Hürny C., Bernhard J., Gelber R.D., Coates A., Castiglione M., Isler M., Dreher D., Peterson H., Goldhirsch A., Senn H.J., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Quality of Life Measures for Patients Receiving Adjuvant Therapy for Breast Cancer: An International Trial. European Journal of Cancer. 28: 1, 118-124, 1992.
 81. The International Breast Cancer Study Group. (Spataro V., Price K., Goldhirsch A., Cavalli F., Simoncini E., Castiglione M., Rudenstam C-M., Collins J., Lindtner J., Gelber R.D., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Sequential Estrogen Receptor Determinations from Primary Breast Cancer and at Relapse: Prognostic and Therapeutic Relevance. Annals of Oncology 3: 733-740, 1992.
 82. The International Breast Cancer Study Group. (Gelber R.D., Goldhirsch A., Cole B.F., Collins J., Snyder R.D., Schwarz M.A. et al : For the Anti-Cancer Council of Victoria). Evaluation of Effectiveness: Q - Twist. Cancer Treatment Reviews 19 (Supplement A) : 73-84, 1993.
 83. The International Breast Cancer Study Group (Gelber R.D., Goldhirsch A., Coates A.S., Collins J., Snyder R.D., Schwarz M.A. et al : For the Anti-Cancer Council of Victoria). Adjuvant Therapy for Breast Cancer: Understanding the Overview. Journal of Clinical Oncology 11: 3, 580-585, 1993.
 84. The International Breast Cancer Study Group (Senn H.J., Castiglione M.,

- Goldhirsch A., Gelber R., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Survey of International Breast Cancer Group (IBCSG) Trials - And An Optimistic Look For Innovative Studies in the Future. In: Adjuvant Therapy of Cancer VII: Sydney E. Salmon, Editor. J.B. Lippincott, Philadelphia, 1993. pp 162-174.
85. The International Breast Cancer Study Group (Hürny C., Bernhard J., Coates A.S., Castiglione M., Peterson H., Gelber R.D., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Timing of Baseline Quality of Life Assessment in an International Adjuvant Breast Cancer Trial: Its Effect on Patient Estimation. *Ann Oncol* 5: 65-74, 1994.
 86. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Price K., Castiglione M., Coates A.S., Rudenstam C.M., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Effect of Systemic Adjuvant Treatment on First Sites of Breast Cancer Relapse. *Lancet* 343: 377-381, 1994.
 87. The International Breast Cancer Study Group (Castiglione-Gertsch M., Johnsen C., Goldhirsch A., Gelber R.D., Collins S.J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 Years' Follow Up. *Ann Oncol* 5: 717-724, 1994.
 88. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., Price K.N., Collins S.J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Present and Future Projects of the International Breast Cancer Study Group. *Cancer* (supplement August 1) 74: 1139-1149, 1994.
 89. The International Breast Cancer Study Group (Nathan B., Gusterson D., Gelber R.D., Reed R., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Expression of BCL-2 in Primary Breast Cancer and its Correlation with Tumour Phenotype. *Ann Oncol* 5: 409-414, 1994.
 90. The International Breast Cancer Study Group (Goldhirsch A., Gelber R., Castiglione M., Price K.N., Collins J., Snyder R.D., Schwarz M.A. et al: for the Anti-Cancer Council of Victoria). Present and Future Projects of the International Breast Cancer Study Group. *Isr J Med Sci* 31 :144-145, 1995.
 91. The International Breast Cancer Study Group (Crivellari D., Price K.N., Hagen M., Goldhirsch A., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Routine Tests During Follow-up of Patients after Primary Treatment for Operable Breast Cancer. *Ann Oncol* 6: 769-776, 1995.
 92. Haines I.E., Lethborg C., and Schwarz M.A. Palliative Care Teaching, What Can We Learn? *Psycho-Oncology* 4 : 311-320, 1995.
 93. The International Breast Cancer Study Group (Marini G., Murray S., Goldhirsch A., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). The Effect of Adjuvant Prednisone Combined with CMF on Patterns of Relapse and Occurrence of Second Malignancies in Patients with Breast Cancer. *Ann Oncol* 7: 245-250, 1996.
 94. The International Breast Cancer Study Group (Hürny C., Bernhard J., Coates A.S., Castiglione-Gertsch M., Collins J., Snyder R.D., Schwarz M.A. et al: for

- the Anti-Cancer Council of Victoria). Impact of Adjuvant Therapy on Quality of Life in Women with Node Positive Operable Breast Cancer. *Lancet* 347: 1279-1284, 1996.
95. The International Breast Cancer Study Group (Castiglione-Gertsch M., Goldhirsch A., Reed R., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Duration and Reintroduction of Adjuvant Chemotherapy for Node-Positive Premenopausal Breast Cancer Patients. *J Clin Onc* 14: 6, 1885-1894, 1996.
 96. The International Breast Cancer Study Group (Hürny C., Bernhard J., Coates A.S., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Responsiveness of a Single-Item Indicator Versus a Multi-Item Scale: Assessment of Emotional Wellbeing in an International Adjuvant Breast Cancer Trial. *Med Care* 34: 3, 234-248, 1996.
 97. The International Breast Cancer Study Group (Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Reed R., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Prognostic Importance of C-ERB B-2 Expression in Breast Cancer. *Classic Papers and Current Comments* 1: 1, 32-40, 1996.
 98. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Simes J., Glasziou P., Coates A.S., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Costs and Benefits of Adjuvant Therapy in Breast Cancer: A Quality-Adjusted Survival Analysis. *Classic Papers and Current Comments* 1: 1, 152-160, 1996.
 99. The International Breast Cancer Study Group (Wallgren A., Bernier J., Gelber R.D., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Timing of Radiotherapy and Chemotherapy Following Breast-Conserving Surgery for Patients with Node Positive Breast Cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 35: 4, 649-659, 1996.
 100. The International Breast Cancer Study Group (Castiglione-Gertsch M., Goldhirsch A., Gusterson R., Reed R., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Effectiveness of Adjuvant Chemotherapy in Combination with Tamoxifen for Node Positive Post Menopausal Breast Cancer Patients. *J. Clin. Onc.* 15: 4, 1385-1394; 1997.
 101. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., O'Neill A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Menstrual Cycle and Timing of Breast Surgery in Premenopausal Node Positive Breast Cancer: Results of the IBCSG Trial VI. *Ann. Oncol.* 8: 751-756; 1997.
 102. The International Breast Cancer Study Group (Castiglione-Gertsch M., Tattersall M., Hacking A., Coates A.S., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Retreating Recurrent Breast Cancer with the Same CMF-Containing Regimen Used as Adjuvant Therapy. *European Journal of Cancer* 33 (14): 2321-2325; 1997.
 103. The International Breast Cancer Study Group (Bernhard J., Hürny C., Coates A.S., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Quality of Life Assessment in Patients Receiving Adjuvant Therapy for Breast Cancer: The IBCSG Approach. *Ann. Oncol.* 8: 825-835; 1997.
 104. The International Breast Cancer Study Group (Bernhard J., Peterson H.,

- Coates A.S., Gusset H., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Quality of Life Assessment in International Breast Cancer Study Group (IBCSG) Trials: Practical Issues and Factors Associated with Missing Data. *Statistics in Medicine* 17: 587-601; 1998.
105. The International Breast Cancer Study Group (Goldhirsch A., Coates A.S., Colleoni M., Castiglione-Gertsch M., Collins J., Snyder R.D., Schwarz M.A. et al: for the Anti-Cancer Council of Victoria). Adjuvant Chemoendocrine Therapy in Post Menopausal Breast Cancer: Cyclophosphamide, Methotrexate, and Fluorouracil. Dose and Schedule May Make a Difference. *J. Clin. Onc.* 16 (4) : 1358-1362; 1998.
 106. Talbot S., Dowling A., Fuller A., Dowling J.P., and Schwarz M.A. Mediastinal Nodal Tuberculosis Presenting as Immune Thrombocytopaenia. *Aust. NZ. J. Med* 28: 465-466; 1998.
 107. The International Breast Cancer Study Group (Pagani O., O'Neill A., Castiglione M., Collins J., Snyder R.D., Schwarz M.A. et al: for the Anti-Cancer Council of Victoria). Prognostic Impact of Amenorrhoea After Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients with Axillary Node Involvement: Results of The International Breast Cancer Study Group (IBCSG) Trial VI. *Eur. J. Cancer* 34: 5, 632-640, 1998.
 108. The International Breast Cancer Study Group (Colleoni M., Price K., Castiglione-Gertsch M., Collins S.J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Dose-Response Effect of Adjuvant Cyclophosphamide, Methotrexate, 5-Fluorouracil (CMF) in Nodepositive Breast Cancer. *Eur. J. Cancer* 34:11, 1693-1700, 1998.
 109. The International Breast Cancer Study Group (Gelber R.D., Bonetti M., Cole B.F., Goldhirsch A., Collins J., Gregory P., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Quality of Life Assessment in the Adjuvant Setting: Is it Relevant? In: *Recent Results in Cancer Research: Adjuvant Therapy of Primary Breast Cancer VI*. H.J. Senn, R. Gelber, A. Goldhirsch, B. Thürlimann, Editors, Springer-Verlag, Berlin, 1998. pp 373-389.
 110. The International Breast Cancer Study Group (Hürny C., Bernhard J., Coates A., Collins J., Gregory P., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Quality of Life Assessment in the International Breast Cancer Study Group: Past, Present and Future. In: *Recent Results in Cancer Research: Adjuvant Therapy of Primary Breast Cancer VI*. H.J. Senn, R. Gelber, A. Goldhirsch, B. Thürlimann, Editors, Springer-Verlag, Berlin, 1998. pp 390-395.
 111. The International Breast Cancer Study Group (Colleoni M., Price K.N., Castiglione-Gertsch M., Gelber R.D., Coates A.S., Goldhirsch A., Collins J., Gregory P., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Mortality During Adjuvant Treatment of Early Breast Cancer with Cyclophosphamide, Methotrexate and Fluorouracil. *Lancet* 354:130-131, 1999.
 112. The International Breast Cancer Study Group (Cote R.J., Peterson H.F., Chaiwun B., Gelber R.D., Goldhirsch A., Castiglione-Gertsch M., Gusterson B., Neville A.M., Collins J., Gregory P., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Role of Immunohistochemical Detection of Lymph Node Metastases in Management of Breast Cancer. *Lancet* 354: 896-900, 1999.

113. The International Breast Cancer Study Group (Sabbioni M.E., Castiglione-Gertsch M., Hürny C., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Interaction of Tamoxifen with Concurrent Cytotoxic Adjuvant Treatment Affects Lymphocytes and Lymphocyte-Subsets Counts in Breast Cancer Patients. *Supportive Care In Cancer* 7(3):149-153, 1999.
114. The International Breast Cancer Study Group (Aebi S., Gelber S., Castiglione-Gertsch M., Collins J., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Is Chemotherapy Alone Adequate for Young Women with Oestrogen-Receptor-Positive Breast Cancer? *Lancet* 355: 1869-1874, 2000.
115. The International Breast Cancer Study Group (Colleoni M., Bonetti M., Coates A.S., Collins J., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Early Start of Adjuvant Chemotherapy may Improve Treatment Outcome for Premenopausal Breast Cancer Patients with Tumours not Expressing Oestrogen Receptors. *J. Clin. Onc.* 18(3): 584-590, 2000.
116. The International Breast Cancer Study Group (Crivellari D., Bonetti M., Castiglione-Gertsch M., Gelber R.D., Collins J., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients with Breast Cancer: The International Breast Cancer Study Group Trial VII. *J. Clin. Onc.* 18(7): 1412-1422, 2000.
117. The International Breast Cancer Study Group (Sabbioni M.E., Siegrist H.P., Goldhirsch A., Hürny C., Collins J., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Association Between Immunity and Prognostic Factors in Early Stage Breast Cancer Patients before Adjuvant Treatment. *Breast Cancer Research and Treatment* 59: 279-287, 2000.
118. The International Breast Cancer Study Group (Coates A.S., Hürny C., Peterson H.F., Gelber R.D., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Quality-of-Life Scores Predict Outcome in Metastatic but not Early Breast Cancer. *J. Clin. Onc.* 18(22): 3768-3774, 2000.
119. The International Breast Cancer Study Group (Colleoni M., O'Neill A., Goldhirsch A., Gelber R.D., Coates A.S., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Identifying Breast Cancer Patients at High Risk for Bone Metastases. *J. Clin. On.* 18(23): 3925- 3935, 2000.
120. The International Breast Cancer Study Goup (Castiglione-Gertsch M., Gelber R.D., Coates A.S., O'Neill A., Goldhirsch A., Collins S.J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Systemic Adjuvant Treatment for Premenopausal Node-Negative Breast Cancer. *Eur. J. Cancer* 36: 549-550, 2000.
121. The International Breast Cancer Study Group (Kitchen P.R.B., Smith H.J., Henderson M.A., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Tubular Carcinoma of the Breast : Prognosis and Response to Adjuvant Systemic Therapy. *ANZ J. Surg.* 71: 27-31, 2001.
122. Toner G.C., Neerhut G.J., **Schwarz M.A.**, Thursfield V.J., Sandeman T.F., Giles G.G. and Snow R.M. The Management of Testicular Cancer in Victoria, 1988-1993. *Medical Journal of Australia* 174: 328-331, 2001.

123. The Australian and New Zealand Germ Cell Trial Group (Toner G.C., Stockler M.R., Boyer M.J., Jones M., Thomson D.B., Harvey V.J., Olver I.N., Dhillon H., McMullen A., Gebiski V.J., Levi J.A., Simes R.J., **Schwarz M.A.**, et al) Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ-Cell Tumors : A Randomized Trial. *Lancet* 357: 739-745, 2001.
124. The International Breast Cancer Study Group (Gusterson B.A., Gelber R.D., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Prognostic Importance of C-erbB-2 Expression in Breast Cancer. *J. Clin. Oncol / Classic Papers and Current Comments* 5: 908-916, 2001.
125. The International Breast Cancer Study Group (Gelber S., Coates A.S., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Effect of Pregnancy on Overall Survival After the Diagnosis of Early Stage Breast Cancer. *J. Clin. Oncol.* 19(6):1671-1675, 2001.
126. The International Breast Cancer Study Group (Colleoni M., Gelber S., Coates A.S., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Influence of Endocrine- Related Factors on Response to Perioperative Chemotherapy for Patients with Node Negative Breast Cancer. *J. Clin. Oncol.* 19(21): 4141-4149, 2001.
127. International breast Cancer Study Group. (Thülimann B., Price K.N., Castiglione M., Coates A.S., Collins J., **Schwarz M.A.**, et al: For the Anticancer Council of Victoria). Randomized Controlled Trial of Ovarian Function Suppression plus Tamoxifen versus the same Endocrine Therapy plus Chemotherapy: Is Chemotherapy Necessary for Premenopausal Women with Node-Positive, Endocrine Responsive Breast Cancer? First results of International Breast Cancer Study Group Trial 11-93. *The Breast* 10 (Suppl 3): 130-138, 2001.
128. The International Breast Cancer Study Group (Bonetti, M., Gelber R.D., Goldhirsch A., Castiglione-Gertsch M., Collins J., **Schwarz M.A.**, et al: For the Anticancer Council of Victoria). Features that Predict Responsiveness to Chemotherapy and Endocrine Therapies. *The Breast* 10 (Suppl 3): 147-157, 2001.
129. The International Breast Cancer Study Group (Goldhirsch A., Coates A.S., Collins J., **Schwarz M.A.**, et al: For the Cancer Council of Victoria). Endocrine Responsiveness and Tailoring Adjuvant Therapy for Post Menopausal Lymph Node Negative Breast Cancer: A Randomized Trial. *J Natl Cancer Inst.* 94: 1054-1065, 2002.
130. The International Breast Cancer Study Group (Colleoni M., Litjman H.J., Collins J., **Schwarz M.A.**, et al: For the Cancer Council of Victoria). Duration of Adjuvant Chemotherapy for Breast Cancer: A Joint Analysis of Two Randomized Trials Investigating Three versus Six Courses of CMF. *Br.J.Cancer* 86: 1705-1714, 2002.
131. The International Breast Cancer Study Group (Wallgren A., Bonetti M., Gelber R.D., Coates A.S., Collins J., **Schwarz M.A.**, et al : For the Cancer Council of Victoria). Risk Factors for Locoregional Recurrence Among Breast Cancer Patients: Results from International Breast Cancer Study Group Trials I Through VII..*Clin.Oncol* 21 (7) : 1205-1213, 2003.
132. The International Breast Cancer Study Group (Trihia H., Murray S., Price K., Gelber R.D., Coates A.S., Collins J., **Schwarz M.A.**, et al : For the Cancer

- Council of Victoria). Ki-67 Expression in Breast Carcinoma: Its Association with Grading Systems, Clinical Parameters, and other Prognostic Factors – A Surrogate Marker? Cancer 97 (5): 1321 –1331, 2003.
133. The International Breast Cancer Study Group (Spataro V.J., Litman H., Viale G., Collins J., Coates A.S., **Schwarz M.A.**, et al: For the Cancer Council of Victoria). Decreased Immunoreactivity for p27 protein in Patients with Early Stage Breast Carcinoma is Correlated with HER-2/neu Overexpression and with Benefit from One Course of Perioperative Chemotherapy in Patients with Negative Lymph Node Status : Results from International Breast Cancer Study Group Trial V. Cancer 97 (7) : 1591-1600, 2003.
 134. The International Breast Cancer Study Group (Castiglione-Gertsch M., O'Neill A., Price K.N., Goldhirsch A., Coates A.S., Collins J., **Schwarz M.A.**, et al : For The Cancer Council of Victoria). Adjuvant Chemotherapy followed by Goserelin versus Either Modality Alone for Premenopausal Lymph Node Negative Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 95: 1833 – 1846, 2003.
 135. The International Breast Cancer Study Group (Crivellari D., Price K., Gelber R.D., Coates A.S., Collins J., Goldhirsch A., **Schwarz M.A.**, et al : For The Cancer Council of Victoria). Adjuvant Endocrine Therapy Compared With No Systemic Therapy For Elderly Women With Early Breast Cancer: 21 year Results of International Breast Cancer Study Group Trial IV. J.Clin.Oncol 21: 4517–4523, 2003.
 136. X-ACT Study Group: Scheithauer W., McKendrick J., Begbie M., Burns W.I., Burris H. A., Cassidy J., Jodrell D., Kore lewski P., Levine E. L., Marschner N., Maroun J., Garcia-Alfonso P., Tujakowski J., Van Hazel G., Wong A., Zaluski J., Twelves C., **Schwarz M.A.**, et al : Oral Capecitabine as an Alternative to i.v. 5-Fluorouracil-based Adjuvant Therapy for Colon Cancer : Safety Results of a Randomized, Phase III Trial. Annals of Oncology 14:1735 – 1743, 2003.
 137. The International Breast Cancer Study Group (Gelber R.D., Bonetti M., Castiglione-Gertsch M., Coates A.S., Goldhirsch A., **Schwarz M.A.**, et al : For The Cancer Council of Victoria). Tailoring Adjuvant Treatments for the Individual Breast Cancer Patient. The Breast 12:558 – 568, 2003.
 138. The International Breast Cancer Study Group (Biganzoli L., Goldhirsch A., Straehle C., Piccart M.J., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Adjuvant Chemotherapy in Elderly Patients with Breast Cancer: A Survey of the Breast International Group (BIG). Annals of Oncology 15: 207 – 210, 2004.
 139. The International Breast Cancer Study Group (Berclaz G., Li S., Price K.N., Coates A.S., Goldhirsch A., **Schwarz M.A.**, et al : For The Cancer Council of Victoria). Body Mass Index as a Prognostic Feature in Operable Breast Cancer: The International Breast Cancer Study Group Experience. Annals of Oncology 15: 875 – 884, 2004.
 140. Loi S., Haydon A.M.M., Shapiro J., **Schwarz M.A.**, and Schneider H.G. Towards Evidence- Based Use of Serum Tumour Marker Requests: An Audit of Use in a Tertiary Hospital: Internal Medicine Journal 34: 545 – 550, 2004.
 141. The International Breast Cancer Study Group (Bernhard J., Zahrieh D., Coates A.S., Gelber R.d., **Schwarz M.A.**, et al : For The Cancer Council of

- Victoria). Quantifying Trade-Offs: Quality of Life and Quality-Adjusted Survival in a Randomised Trial of Chemotherapy in Postmenopausal Patients with Lymph Node-Negative Breast Cancer: British Journal of Cancer 91: 1893 – 1901, 2004.
142. Koczwara B., Tattersall M. H. N., Barton M. B., Coventry B. J., Dewar J. M., Millar J. L., Olver I. N., **Schwarz M.A.**, Starmer D. L., Turner D. R., and Stockler M. R., For The Cancer Council of Australia Oncology Education Committee. Achieving Equal Standards in Medical Student Education: Is a National Exit Examination the Answer? Medical Journal Australia 182 (5) : 228 – 230, 2005
 143. The International Breast Cancer Study Group (Colleoni M., Zahrieh D., Gelber R.D., Holmberg S.B., Goldhirsch A., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Site Of Primary Tumour Has A Prognostic Role In Operable Breast Cancer: The International Breast Cancer Study Group Experience: Journal of Clinical Oncology 23: 1390 – 1400, 2005.
 144. The International Breast Cancer Study Group (Colleoni M., Li S., Gelber R.D., Coates A.S., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Timing of CMF Chemotherapy in Combination with Tamoxifen in Postmenopausal Women with Breast Cancer: Role of Endocrine Responsiveness of the Tumor. Annals of Oncology 16: 716 – 725, 2005.
 145. The International Breast Cancer Study Group (Gruber G., Bonetti M., Nasi L., Goldhirsch A., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Prognostic Value of Extracapsular Tumour Spread for Locoregional Control in Premenopausal Patients with Node-Positive Breast Cancer Treated with Classical Cyclophosphamide, Methotrexate and Fluorouracil: Long-Term Observations From International Breast Cancer Study Group Trial VI. Journal of Clinical Oncology 23: 7089 – 7097, 2005.
 146. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) Trial Group: Capecitabine As Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med 352: 2696-2704, 2005.
 147. Iressa Survival Evaluation in Lung Cancer (ISEL) Trial Group: Gefitinib Plus Best Supportive Care in Previously Treated Patients with Refractory Advanced Non-small-cell Lung Cancer: Results From a Randomised, Placebo-Controlled, Multicentre Study. Lancet 366:1527 –1537, 2005.
 148. Koczwara B., Barton M., Coventry B., Millar J., Olver I., Sabesan S., Schwarz M.A. Cancer Curriculum in the Asia-Pacific: Opportunities and Challenges in the Age of Globalisation. Asia-Pacific Journal of Clinical Oncology 1: 109 – 113, 2005.
 149. The International Breast Cancer Study Group (Rudenstam C. M., Zahrieh D., Forbes J. F., Collins J., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology 24: 337 – 344, 2006.
 150. Curr N., Saunders H., Murugasu A., Cooray P., Schwarz M.A. and Gin D.: Multiple Periungual Pyogenic Granulomas Following Systemic 5-Fluorouracil. Aust. Journal of Dermatology 47: 130 – 133, 2006.
 151. The International Breast Cancer Study Group (Pestalozzi B.C., Zahrieh D.,

- Price K.N., Gelber R.D., Collins J., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Identifying Breast Cancer Patients At Risk For Central Nervous System (CNS) Metastases In Trials Of The International Breast Cancer Study Group (IBCSG). *Annals of Oncology* 17: 935 – 944, 2006.
152. The International Breast Cancer Study Group (Regan M.M., Viale G., Mastropasqua M.G., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. *J Natl Cancer Inst.* 98: 1571-1581, 2006.
153. The International Breast Cancer Study Group (Gianni L., Panzini I., Gelber R.D., Collins J., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Ocular Toxicity During Adjuvant Chemoendocrine Therapy For Early Breast Cancer. *Cancer* 106: 505 – 513, 2006.
154. Philip J., Gold M., **Schwarz M.A.**, Komesaroff P. Anger In Palliative Care: A Clinical Approach. *Internal Medicine Journal* 37: 49-55, 2007.
155. The International Breast Cancer Study Group (Bernhard J., Zahrieh D., Castiglione-Gertsch M., Coates A.S., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Adjuvant Chemotherapy Followed by Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients. The International Breast Cancer Study Group Trial VIII. *Journal of Clinical Oncology* 25:263 – 270, 2007
156. The International Breast Cancer Study Group (Keshaviah A., Dellapasqua S., Rotmensz N., Coates A.S., Goldhirsch A., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). CA 15-3 and Alkaline Phosphatase as Predictors for Breast Cancer Recurrence: a Combined Analysis of Seven International Breast Cancer Study Group Trials. *Annals of Oncology* 18: 701 – 708, 2007.
157. The International Breast Cancer Study Group (Collins J., Snyder R., Abdi E., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Effects of a Treatment Gap During Adjuvant Chemotherapy in Node-positive Breast Cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. *Annals of Oncology* 18: 1177 – 1184, 2007.
158. Roithmaier S., Haydon A.M., Loi S., Esmore D., Griffiths A., Bergin P., Williams T.J., and Schwarz M.A. Incidence of Malignancies in Heart and/or Lung Transplant Recipients: A Single-Institution Experience. *The Journal of Heart And Lung Transplantation* 26:8, 845 – 849, 2007.
159. The International Breast Cancer Study Group (Francis P., Crown J., Di Leo A., Goldhirsch A., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Adjuvant Chemotherapy With Sequential Or Concurrent Anthracycline And Docetaxel: Breast International Group 02-98 Randomized Trial. *J Natl Cancer Inst.* 100:121 - 133, 2008.
160. The International Breast Cancer Study Group (Lorenzo G., Cole B.F., Panzini I., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Anaemia During Adjuvant Non-Taxane Chemotherapy For Early Breast Cancer: Incidence And Risk Factors From Two Trials Of The International Breast Cancer Study Group. *Support Care Cancer* 16:67 - 74, 2008.
161. The International Breast Cancer Study Group (Viale G., Regan M.M., Coates A.S., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of

- Victoria). Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. *J Natl Cancer Inst.* 100: 207-212, 2008.
162. The International Breast Cancer Study Group (Viale G., Regan M.M., Coates A.S., Collins J., Snyder R., Brown B., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors – International Breast Cancer Study Group. *Journal of Clinical Oncology* 26:1404 - 1410, 2008.
 163. The International Breast Cancer Study Group (Ravaioli A., Monti F., Regan M.M., Viale G., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). p27 and Skp2 Immunoreactivity and its Clinical Significance with Endocrine and Chemo-Endocrine Treatments In Node-Negative Early Breast Cancer. *Annals of Oncology* 19: 660 - 668, 2008.
 164. The International Breast Cancer Study Group (Gruber G., Cole B.F., Castiglione-Gertsch M., Holmberg S.B., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Extracapsular Tumor Spread and the Risk of Local, Axillary and Supraclavicular Recurrence in Node-Positive, Premenopausal Patients with Breast Cancer. *Annals of Oncology* 19: 1393 - 1401, 2008.
 165. Hawkes E., Haydon A., Murugasu A., and Schwarz M.A. Inferior Vena Caval Leiomyosarcoma in a Patient With Past Bilateral Retinoblastoma. *Asia-Pacific Journal of Clinical Oncology* 4: 181 – 183, 2008.
 166. The International Breast Cancer Study Group (Gianni L., Gelber S., Coates A.S., Goldhirsch A., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Second Non-Breast Primary Cancer Following Adjuvant Therapy for Early Breast Cancer: A Report from the International Breast Cancer Study Group. *European Journal of Cancer* 45: 561 –571, 2009.
 167. The International Breast Cancer Study Group (Thurlimann B., Price K.N., Gelber R.D., Coates A.S., Goldhirsch A., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Is Chemotherapy Necessary for Premenopausal Women with Lower-Risk Node Positive, Endocrine Responsive Breast Cancer? 10-year Update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Res Treatment* 113: 137 – 144, 2009.
 168. Philip J., Gold M., **Schwarz M.A.**, and Komesaroff P.: Patients' Views on Decision Making in Advanced Cancer. *Palliative and Supportive Care* 7: 181 – 185, 2009.
 169. The International Breast Cancer Study Group (Pagani O., Gelber S., Simoncini E., Castiglione-Gertsch M., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Is Adjuvant Chemotherapy of Benefit for Postmenopausal Women Who Receive Endocrine Treatment for Highly Endocrine-Responsive, Node-Positive Breast Cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Res Treat* 116:491 - 500, 2009.
 170. Bell R J., Lijovic M., Fradkin P., Bradbury J., La China M., **Schwarz M.A.**, Wolfe R., Farrugia H., Davis S.R. Lack Of Knowledge of Hormone Receptor Status and Use of Endocrine Therapy in Invasive Breast Cancer.

- Journal of Women's Health 18:12, 1975-1980, 2009.
171. Lijovic M., Davis S.R., Fradkin P., Bradbury J., La China M., **Schwarz M.A.**, Wolfe R., Farrugia H., Bell R J. The Relationship Between Knowledge of Family History and Cancer Characteristics at Diagnosis in Women Newly-Diagnosed with Invasive Breast Cancer. *Familial Cancer* 8: 299-305, 2009.
 172. The International Breast Cancer Study Group (Viale G., Giobbie-Hurder A., Gusterson B.A., Gelber R.D., Goldhirsch A., Coates S.A., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Adverse Prognostic Value of Peritumoral Vascular Invasion: Is It Abrogated by Adequate Endocrine Adjuvant Therapy? Results From Two International Breast Cancer Study Group Randomized Trials of Chemoendocrine Adjuvant Therapy for early Breast Cancer. *Annals of Oncology* 21: 245-254, 2010.
 173. Philip J., Gold M., **Schwarz M.A.**, Komesaroff P. Second Medical Opinions: The Views of Oncology Patients and their Physicians. *Support Care In Cancer*: 18: 9, 1199-1205, 2010.
 174. Bell R.J., Lijovic M., La China M., **Schwarz M.A.**, Fradkin P., Bradbury J., Davis S.R. Psychological Well-Being in a Cohort of Women with Invasive Breast Cancer Nearly 2 Years after Diagnosis. *Support Care Cancer*: 18, 921- 929, 2010.
 175. Diez B.D., Statkevich P., Zhu Y., Abutarif M. A., Xuan F., Kantesaria B., Cutler D., Cantillon M., **Schwarz M.A.**, Pallotta M. G., Ottaviano F. H. Evaluation of the Exposure Equivalence of Oral Versus Intravenous Temozolomide. *Cancer Chemother Pharmacol.* 65 (4): 727-734, 2010.
 176. Davis S R., Lijovic M., Fradkin P., Bradbury J., La China M., **Schwarz M.A.**, and Bell R.J. Use of Complementary and Alternative Therapy by Women in the First Two Years Following Dianosis and Treatment of Invasive Breast Cancer. *Menopause* 17:5, 1004-1009, 2010.
 177. Panjari M., Bell R.J., Lijovic M., La China M., **Schwarz M.A.**, Fradkin P., Bradbury J., Farraugia H., Davis S.R. The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumour Characteristics: a Cohort Study *Hormones and Cancer* 1: 93-99, 2010.
 178. Philip J., Gold M., **Schwarz M.A.**, Komesaroff P. An Exploration of the Dynamics and Influences upon Second Medical Opinion Consultations in Cancer Care. *Asia Pac J Clin Oncol* (1): 41-46, 2011.
 179. The International Breast Cancer Study Group (Karlsson P., Sun Z., Coates A.S., Goldhirsch A., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Longterm Results of International Breast Cancer Study Group Trial VIII: Adjuvant Chemotherapy plus Goserelin Compared With Either Therapy Alone for Premenopausal Patients With Nodenegative Breast Cancer. *Annals of Oncology*: 22:2216-2226, 2011.
 180. The International Breast Cancer Study Group (Aebi S., Sun Z., Coates A.S., Goldhirsch A., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Differential Efficacy of Three Cycles of CMF Followed By Tamoxifen in Patients with ER Positive and ER Negative Tumours: Long-Term Follow Up on IBCSG Trial IX. *Annals of Oncology*: 22: 1981-1987, 2011
 181. Slamon D, et al: For The Breast Cancer International Research Group: (BCIRG-006 Study) Adjuvant Trastuzumab in Her 2 –Positive Breast Cancer. *The New England Journal of Medicine* 365:1273-1283, 2011.

182. Bell R.J., Lijovic M., Fradkin P., **Schwarz M.A.**, Davis S.R. Changes in Patterns of Use of Cigarettes and Alcohol in Women after a First Diagnosis of Invasive Breast Cancer: A Cohort Study of Women from Victoria, Australia. *Supportive Care in Cancer*: 20, 783-789, 2012.
183. Bell R.J., Robinson P.J., Fradkin P., **Schwarz M.A.**, Davis S.R. Breast Reconstruction Following Mastectomy for Invasive Breast Cancer is Strongly Influenced by Demographic Factors in Women in Victoria, Australia. *The Breast* 21:3, 394-400, 2012.
184. Bell R.J., Fradkin P., **Schwarz M.A.**, Davis S.R. Understanding Discontinuation of Oral Adjuvant Endocrine Therapy by Women with Hormone Receptor Positive Invasive Breast Cancer Nearly 4 Years from Diagnosis. *Menopause* 20:1, 15-21, 2013.
185. Bell R.J., **Schwarz M.A.**, Fradkin P., Davis S.R. Use of Imaging in Surveillance of Women with Early Stage Breast Cancer. *ANZ J Surg*: 83, 129-134, 2013.
186. Bell R.J., **Schwarz M.A.**, Fradkin P., Robinson P.J., Davis S.R. Patterns of Use of Oral Adjuvant Endocrine Therapy in Australian Breast Cancer Survivors 5 years from Diagnosis. *Menopause* 20 (1): 15-21, 2013.
187. Bell R.J., Robinson P.J., Barallon R., Fradkin P., **Schwarz M.A.**, Davis S.R. Lymphedema: Experience of a Cohort of Women with Breast Cancer Followed for 4 years after Diagnosis in Victoria, Australia. *Supportive Care in Cancer*: 21, 2017-2024, 2013.
188. The International Breast Cancer Study Group (Metzger-Filho O., Sun Z., Viale G., Price K.N., Crivellari D., Coates A.S., Goldhirsch A., Cardoso F., Collins J., Snyder R., **Schwarz M.A.**, et al: For The Cancer Council of Victoria). Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node – Negative Disease: Results from International Breast Cancer Study Group Trials VIII and IX. *Journal of Clinical Oncology* 31:25, 3083 –3090, 2013.
189. Bell R.J., Fradkin P., Parathithasan N., Robinson P.J., **Schwarz M.A.**, Davis S.R. Pregnancy-Associated Breast Cancer and Pregnancy Following Treatment for Breast Cancer, in a Cohort of Women from Victoria, Australia, with a First Diagnosis of Invasive Breast Cancer. *The Breast*, 22: 980 – 985, 2013.
190. Bell R.J., Robinson P.J., Nazeem F., Panjari M., Fradkin P., **Schwarz M.A.**, Davis S.R. Persistent Breast Pain 5 years After Treatment of Invasive Breast Cancer is Largely Unexplained by Factors Associated with Treatment. *J Cancer Survival*, 8:1, 1-8, 2014.
191. Panjari M., Robinson P.J., Davis S.R., **Schwarz M.A.**, Bell R.J. A Comparison of the Characteristics, Treatment and Outcome after 5 years, of Australian Women Aged 70+ with those Aged <70 years at the Time of Diagnosis of Breast Cancer. *Journal of Geriatric Oncology*. 5:2, 141 – 147, 2014.
192. Bell R.J., Fradkin P., Robinson P.J., **Schwarz M.A.**, Davis S.R. Intended Follow-up of Women with Breast Cancer at Low Risk of Recurrence and at least 5 years from Diagnosis *Internal Medicine Journal*. 44:4, 332-338, 2014.

BOOK CHAPTERS

Principles of Medical Therapy: George M., Schwarz M., and McKinnon R.

In:

Sabesan S, Olver I, editors. Clinical Oncology for Medical Students. Sydney: Cancer Council, Australia

B. ABSTRACTS

1. Tauro G.P., Danks D.M., Rowe P.B., Van der Weyden M.B., **Schwarz M.A.**, Collins V.L. and Neil B.W.: Dihydrofolate Reductase Deficiency in Two Families. Annual Scientific Meeting of The Haematology Society of Australia, Melbourne. October 11-12, 1976
2. Brodie G.N., and Schwarz M.A.: Indomethacin and Bone Pain. XVIth International Congress of Haematology. 4:107-167, Kyoto, Japan, 1976.
3. Hortobagyi G.N., Gutterman J.U., Blumenschein G., Richman S.P., Schwarz M.A. and Tashima C.K.: Chemotherapy of Advanced Breast Cancer with BCG and MER: Immunotherapy of Cancer: Present Status of Trials in Man. National Cancer Institute, N.I.H., October 27-29, 1976.
4. Gutterman J.U., Hersh E.M., Mavligit G.M., Burgess M.A., Richman S.P., **Schwarz M.A.**, Rodriguez V. and Valdivieso M.: Chemoimmunotherapy of Disseminated Malignant Melanoma with Bacillus Calmette Guerin: 54-Month Follow-Up. In: Immunotherapy of Cancer. Present Status of Trials in Man. National Cancer Institute, N.I.H. October 27-29, 1976.
5. **Schwarz M.A.**, Gutterman J.U., Hersh E.M., Mavligit G.M., and Bodey G.P.: Chemoimmunotherapy of Disseminated Malignant Melanoma with DTIC, BCG, Transfer Factor + Melphalan. Proceedings American Association Cancer Research # 875, May 1977.
6. **Schwarz M.A.**, Gutterman J.U., Burgess M.A. and Hersh E.M.: Chemoimmunotherapy of Disseminated Malignant Melanoma. Proceedings of the Clinical Oncology Society of Australia, December 1977.
7. Schwarz M.A.: Chemotherapy of Testicular Carcinoma. Proceedings of the Clinical Oncology Society of Australia, November 1979.
8. Ludwig Breast Cancer Study Group (Russell I., Schwarz M.A. et al for Anti-Cancer Council of Victoria): Search for Optimal Adjuvant Therapies, Combining Hormone and Chemotherapy in Operable Breast Cancer. Proceedings American Society of Clinical Oncology # 428, May 1981.
9. **Schwarz M.A.**, Hurley R.A. and Rundle H.M.P.: Chemotherapy of Recurrent Nasopharyngeal Carcinoma (Lymphoepithelioma). Proceedings of the clinical Oncology Society of Australia, December 1981.
10. Ludwig I-IV Adjuvant Chemohormonal Therapy Trial In Operable Breast Carcinoma. An Update. Schwarz M.A.: Proceedings of the Royal Australasian College of Radiologists, October 1982.
11. Bisantrene: A Review. Bishop J.F., Coates A., and Schwarz M.A.: Proceedings of the Clinical Oncology Society of Australia, November 1982.
12. Mitoxantrone: The Australian Experience. Raghavan D., Bishop J., **Schwarz M.A.**, Snyder R.D., Burns I., Gill G., Wood R., Coates A., Fox R., Tattersall M. Proceedings of the Clinical Oncology Society of Australia, November 1982.
13. Evaluation of Mitoxantrone for Cardiotoxicity. Mann G., Bishop J., Raghavan

- D., McLaughlin A., Coates A., **Schwarz M.A.**, Wood R., Hedley D., Fox R., Tattersall M. Proceedings of the Clinical Oncology Society of Australia, November 1982.
14. Phase II Study of Mitoxantrone (NSC 301739). Raghavan D., Bishop J., Mann G., Coates A., Woods R., Fox R., Snyder R., **Schwarz M.A.**, Hedley D., Gill P., Tattersall M. Proceedings of the American Association for Cancer Research # 554, May 1983.
 15. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Treatment for Operable Breast Cancer: Chemotherapy and Hormonotherapy. 13th International Congress of Chemotherapy, Vienna, September, 1983. # SE 12.9. 2-3.
 16. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Search for Optimal Adjuvant Therapies Combining Hormonotherapy and Chemotherapy in Operable Breast Cancer. 13th International Congress of Chemotherapy, Vienna, September 1983. # SE 12.8, 5-4.
 17. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Therapy in Post Menopausal Women with Operable Breast Cancer Study III. Adjuvant Therapy of Cancer IV: Tucson, Arizona, March 1984.
 18. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Endocrine Therapy in Post Menopausal Women with Operable Breast Cancer: Study IV: Adjuvant Therapy of Cancer IV: Tucson, Arizona, March 1984.
 19. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): The Role of Oestrogen and Progesterone Receptors in the Choice of Adjuvant Therapy for Post Menopausal Patients with Operable Breast Cancer Studies III and IV: Proceedings of the American Society of Clinical Oncology, Abstract No. C503, May 1984.
 20. A Phase I Trial of 4 Epidoxorubicin Given on a Weekly Schedule: Snyder R.D., Bishop J., Brodie G., Burns I., Coates A., Levi J., Raghavan D., **Schwarz M.A.**, Tattersall M., Thomson D., Woods R., Ziogas V: International Symposium: Advances in Anthracycline Chemotherapy, Milan, June 1984.
 21. Ambulatory Continuous Infusion Chemotherapy Using the Auto-Syringe Pump: Flux M., and Schwarz M.A. Proceedings of the Clinical Oncology Society of Australia, Melbourne, November, 1984.
 22. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Chemotherapy (C.M.F.) With or Without Low Dose Prednisone in Premenopausal Patients with Metastases in 1 to 3 Axillary Lymphnodes: Ludwig Trial 1: Proceedings of the American Society of Clinical Oncology, Abstract No: C204, May 1985.
 23. Carcinoma of the Testis and Extra Gonadal Germ Cell Tumours: Snow R.M., Westmore D.D., Brown R.B. and Schwarz M.A. Proceedings of the Urological Society of Australasia, Perth, April 1986.
 24. Complete Remission in Hairy Cell Leukaemia with Escalating Doses of Recombinant Alpha A Interferon: Holmes R., **Schwarz M.A.**, Whiteside M.G. and Firkin F.C. Proceedings of the International Society of Haematology, Sydney, May 1986.

25. Ludwig Breast Cancer Study Group: (Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Treatment of Post Menopausal Patients with Breast Cancer: Chemo- Endocrine or Endocrine Therapy? Proceedings of the American Society of Clinical Oncology, Abstract No: 298, May 1986.
26. Ludwig Breast Cancer Study Group: (Gelber R.D., Goldhirsch A., Castiglione M., Price K., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Evaluating Adjuvant Treatments from a Quality of Life Viewpoint. Adjuvant Therapy of Cancer V: Tucson, Arizona, March 1987.
27. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Two Generations of Trials in Adjuvant Treatment of Operable Breast Cancer: The Ludwig Breast Cancer Studies I-IV and V. Adjuvant Therapy of Cancer V: Tucson, Arizona, March 1987.
28. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Russell I., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Adjuvant Endocrine Therapy for Elderly Patients with Node Positive Breast Cancer: A Benefit Limited by Competing Causes of Death: Proceedings of the American Society of Clinical Oncology, Abstract No: 201, May 1987.
29. Autoantibodies to Neurons and to the Cytoskeleton in a Case of Small Cell Carcinoma with Paraneoplastic Neuropathy: Alderuccio F., Ashley R., Rolland J.M., Toner G.C., **Schwarz M.A.**, McCluskey J. and Toh B.H. Annual Meeting Royal College of Pathologists of Australasia, Hobart, October 1988.
30. Ludwig Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Collin, J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Patterns of First Relapse in Breast Cancer Patients with Node Negative Disease: The Effect of a Single Cycle of Adjuvant Perioperative Chemotherapy: Proceedings of the American Society of Clinical Oncology, Abstract No: 68, May 1989.
31. Ludwig and International Breast Cancer Study Group (Castiglione M., Gelber R.D., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Systemic Treatment for First Relapse of Breast Cancer After Adjuvant Therapy Using the same Treatment Again: Proceedings of the American Society of Clinical Oncology, Abstract No: 156, May 1989.
32. Ludwig and International Breast Cancer Study Groups (Gelber R.D., Simes J., Coates A., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria): Comparison of Adjuvant Therapies Using Quality-of-Life Considerations: Proceedings of the American Society of Clinical Oncology, Abstract No: 1219, May 1989.
33. An 11 Year Retrospective Analysis of Pleural Mesothelioma at the Alfred Hospital: Cherny N.I., Shanahan A.E., Farash S., Honeybone R., and Schwarz M.A. Proceedings of the Clinical Oncology Society of Australia, November 1989.
34. The International Breast Cancer Study Group (Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam C.M., Senn H.J., Lindtner J., Brunner Y.C., Cavalli F., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Adjuvant Systemic Therapy in Elderly Patients with Node Positive Breast Cancer. Adjuvant Therapy of Cancer VI: Tucson, Arizona, March, 1990.
35. The International Breast Cancer Study Group (Goldhirsch A., Gelber R.D., Castiglione M., Collins J., Schwarz M.A.: For Anti-Cancer Council of

- Victoria). Chemo-Endocrine Adjuvant Therapy has Moderate Effects for Postmenopausal Women with Operable Breast Cancer and Four or more Metastatic Axillary Nodes. Proceedings of the American Society of Clinical Oncology, Vol. 9, Abstract No. 68, March, 1990.
36. The International Breast Cancer Study Group (Gelber R.D., Simes R.J., Castiglione M., Price K., Isley M., Goldhirsch A., Collins J., Schwarz M.A. et al.: For Anti-Cancer Council of Victoria). Evaluating Prognoses and Treatment Effects Using a Quality-of-Life-Oriented End Point (QTWist) Rather than Conventional End Points (Disease Free Survival and Overall Survival) Alone. Proceedings of the American Society of Clinical Oncology, Vol. 9, Abstract No. 1170, March, 1990.
 37. The International Breast Cancer Study Group (Hurny C., Bernhard J., Gelber R.D., Coates A., Castiglione M., Isley M., Dreher D., Senn H.J., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Applying Quality of Life Measures in Trial VI and VII of the International Breast Cancer Study Group: Feasibility Report. Proceedings of the American Society of Clinical Oncology, Vol. 9, Abstract No. 1174, March, 1990.
 38. The International Breast Cancer Study Group (Castiglione M., Goldhirsch A., Gelber R., Collins J., Snyder R., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Adjuvant Treatment for Early Breast Cancer: The International Breast Cancer Studies. U.I.C.C. Congress, Hamburg, 20.20.05, p.1123, August 1990.
 39. The International Breast Cancer Study Group and Eastern Cooperative Oncology Group (Robert, N.J., Gray, R., Gelber, R.D., Goldhirsch, A., Abeloff, D.C., Tormey, D.C., Collins J., Schwarz, M.A. et al: For Anti-Cancer Council of Victoria). Node Positive Breast Cancer: Which Patients are at High Risk? Proceedings of the American Society of Clinical Oncology, Vol. 10, Abstract No. 111, March 1991.
 40. The International Breast Cancer Study Group (Hurny C., Bernhard J., Gelber R.D., Coates A., Peterson H., Castiglione M., Isley M., Senn H.J., Goldhirsch A., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Quality of Life Assessment in I.B.C.S.G. Trials VI and VII: Impact of Time, Language and Treatment in the First 9 Months of Adjuvant Breast Cancer Treatment. Proceedings of the American Society of Clinical Oncology, Vol. 10, Abstract No. 126, March 1991.
 41. The International Breast Cancer Study Group (Hurny C., Bernhard J., Pampaliona S., Tomamichel M., Spek U., Coates A., Castiglione M., Goldhirsch A., Senn H.J., Collins J., Snyder R., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). The Perceived Adjustment to Chronic Illness Scale (PACIS): A Global Indicator of Coping of Operable Breast Cancer Patients for Clinical Trials. Proceedings of Current Concepts in Psycho-Oncology IV, New York, October, 1991.
 42. The International Breast Cancer Study Group (Castiglione M., Price K., Gelber R.D., Senn H.J., Goldhirsch A., Collins J., Snyder R., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Bone Metastases as First Site of Relapse in Breast Cancer Patients Who Underwent Surgery Alone, With or Without Adjuvant Systemic Treatment. Proceedings of E.C.C.O. 6 Conference, Florence, October, 1991.
 43. The International Breast Cancer Study Group. (Hurny C., Bernhard J.,

- Peterson H., Gelber R.D., Coates A., Castiglione M., Goldhirsch A., Senn H.J., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Psychosocial Predictors of Survival in Stage II Breast Cancer Patients: A Preliminary Analysis. Proc Int Ass for Breast Canc Res, 1991.
44. The International Breast Cancer Study Group. (Hurny C., Bernhard J., Peterson H., Gelber R.D., Coates A., Castiglione M., Goldhirsch A., Senn H.J., Collins J., Snyder R.D., Schwarz M.A. et al: For the Anti-Cancer Council of Victoria). Effect of Timing of Assessments on Quality-of- Life Scores of Breast Cancer Patients Receiving Adjuvant Treatment. Proc Int Ass for Breast Canc Res, 1991.
 45. The International Breast Study Cancer Group. (Hurny C., Goldhirsch A., Gelber R.D., Castiglione M., Collins J., Snyder R.D., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Psychosocial Correlates of Estrogen Receptor Status in Breast Cancer. Proc Am Soc Clin Onc 11, Abstract No. 56, March 1992.
 46. Australian & New Zealand Breast Cancer Trials Group. (Forbes J.F., Byrne M., Snyder R.D., Collins J., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Oophorectomy versus Cytotoxic Chemotherapy versus Concurrent Modality Therapy. A Randomized Trial in Premenopausal Women with Advanced Breast Cancer. Proc Am Soc Clin Onc 11, Abstract No.146, March 1992.
 47. The International Breast Cancer Study Group. (Cote R., Chaiwun B., Qu J., Taylor C., Peterson H., Gelber R.D., Goldhirsch A., Neville A.M., Collins J., Snyder R.D., Schwarz M.A. et al: For Anti-Cancer Council of Victoria). Prognostic Importance of Occult Lymph Node Metastases in Patients with Breast Cancer. Proc Am Assoc for Canc Res 33, Abstract 1208, March 1992.
 48. The International Breast Cancer Study Group. (Spataro V., Goldhirsch A., Cavalli F., Castiglione M., Gelber R.D., Collins J., Snyder R.D., Schwarz M.A. et al. : For Anti-Cancer Council of Victoria). Sequential Estrogen Receptor Determinations from Primary Breast Cancer and at Relapse: Prognostic and Therapeutic Relevance. Proceedings of European Society for Medical Oncology, XVII Congress, Lyon, November 1992.
 49. What We Can Learn: Evaluation of a Palliative Care Teaching Programme: Lethborg C., Haines E., Cherny N., and Schwarz M.A. Proceedings of the Australian Association for Hospice and Palliative Care: National Hospice and Palliative Care Conference, Melbourne, October, 1993.
 50. What We Can Learn: Evaluation of a Palliative Care Teaching Programme: Haines I.E., Lethborg C., and Schwarz M.A. Proceedings of the American Society of Clinical Oncology, Abstract no: 1541, May 1994.
 51. The International Breast Cancer Study Group (Bernhard J., Hurny C., Coates A., Peterson H.F., Castiglione M., Gelber R.D., Goldhirsch A., Collins J., Snyder R.D., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Impact of Biomedical, Sociodemographic and Language Factors on Baseline Quality of Life in Two International Adjuvant Breast Cancer Trials. Proc of 5th International Conference of Adjuvant Therapy of Primary Breast Cancer, St. Gallen, February 1995.
 52. The International Breast Cancer Study Group (Johnston P.G., Pestalozzi B.C., Allegra C.J. Gelber R., Gusterson B.A., Byrne M., Rudenstam C-M., Goldhirsch A., Collins J., Snyder R.D., **Schwarz M.A.**, et al : for the Anti-

- Cancer Council of Victoria). The Prognostic Significance of Thymidylate Synthase in Early Breast Cancer. Proc of The American Society of Clinical Oncology, Abstract No. 67, May 1996.
53. Lethborg C., Haines I.E., and Schwarz M.A. Teaching Palliative Care, What The Next Generation of Medical Professionals Say They Need. Proc of the 3rd World Congress of Psycho-Oncology, New York, September 1996.
 54. Taouk Y., Cole-Sinclair M., Elliott P., Rodger A., Schwarer A., and Schwarz M.A. Paradox : An Effective Data Management Tool. Proc of the Clinical Oncological Society of Australia: 23rd Annual Scientific Meeting, November 1996.
 55. The International Breast Cancer Study Group (Sabbioni M., Hurny C.H., Bernhard J., Castiglione M., Siegrist H.P., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Interactions Between Psychosocial Factors and Immunity in Breast Cancer Patients. Proc of the European Society for Medical Oncology, Abstract No. 54P, November 1996.
 56. Taouk Y., Cole-Sinclair M., Elliot P., Rodger A., Schwarer A.P., and Schwarz M.A. The Role of Data Manager in Clinical and Medical Research. Proc. of the Clinical Oncological Society of Australia: 24th Annual Scientific Meeting, November 1997.
 57. The International Breast Cancer Study Group (Bernhard J., Hurny C., Peterson H.F., Gelber R.D., Coates A.S., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Quality of Life Assessments in Patients Receiving Adjuvant Therapy for Breast Cancer. Quality of Life Research 6: 623; 1997.
 58. The International Breast Cancer Study Group (Orlando L., Gelber R.D., Coates A., Goldhirsch A., Collins J., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Early Start of Adjuvant Chemotherapy May Be Important in Premenopausal Patients with ER Negative Breast Cancer. Proceedings of the American Society of Clinical Oncology 17: Abstract No. 629; May 1998.
 59. The International Breast Cancer Study Group (Crivellari D., Bonetti M., Castiglione M., Collins J., Snyder R.D., Schwarz M.A. et al: for the Anti-Cancer Council of Victoria). Adjuvant Treatment of Elderly Patients with Node Positive Breast Cancer: CMF Tolerability in International Breast Cancer Study Group (IBSG) Trial VII. Proceedings of the American Society of Clinical Oncology 17: Abstract No. 394; May 1998.
 60. The International Breast Cancer Study Group (Calleoni M., Price K., Gelber M., Castiglione- Gertsch M., Coates A.S., Collins J., Goldhirsch A., Snyder R.D., Schwarz M.A. et al : for the Anti-Cancer Council of Victoria). Dose-Response Effect of Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil in Node-Positive Breast Cancer. Proceedings of the American Society of Clinical Oncology 17: Abstract No. 508; May 1998.
 61. The International Breast Cancer Study Group (Aebi S., Castiglione-Gertsch M., Collins J., Goldhirsch A., **Schwarz M.A.**, et al: for the Anti-Cancer Council of Victoria). Treatment with Chemotherapy Alone is Inadequate for Very Young Women with Estrogen Receptor Positive, Breast Cancer. Results from the International Breast Cancer Study Group (IBCSG) Trials I, II, V and VI. Proceedings of the American Society of Clinical Oncology 18: Abstract No

- 260, May 1999.
62. The International Breast Cancer Study Group (Coates A., Hurny C., Peterson H.F., Gelber R.D., Goldhirsch A., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Prognostic Value of Pre- and Post-Recurrence Quality of Life (QL) Scores in Patients (Pts) with Node-Positive Breast Cancer Treated Within International Breast Cancer Study Group (IBCSG) Adjuvant Trials. Proceedings of the American Society of Clinical Oncology 18 : Abstract No 280, May 1999.
 63. The International Breast Cancer Study Group (Colleoni M., O'Neill A., Gelber R.D., Coates A.S., Goldhirsch A., Schwarz M.A., et al : for the Anti-Cancer Council of Victoria). Subsequent Sites of Recurrence in Patients with Local, Regional and Soft Tissue Relapse: An Analysis on 1217 Cases. Proceedings of the American Society of Clinical Oncology 18: Abstract No 300, May 1999.
 64. Haydon A., Millar J., Schwarz MA, Cunningham I., Smith RE, Carroll R., and Shapiro J.D. Review of Patients Undergoing Surgery for Rectal Adenocarcinoma at the Alfred Hospital, 1993–1998. Medical Oncology Group of Australia, Annual Meeting, May 2000.
 65. The International Breast Cancer Study Group (Colleoni M., Gelber S., Rudenstam C., Collins J., **Schwarz M.A.**, et al : for the Anti-Cancer Council of Victoria). Prognostic Factors in Node–Negative Patients Untreated with Adjuvant Systemic Therapy or Treated with a Single Course of Perioperative Chemotherapy: Updated Results from the IBCSG Trial V. Proceedings of the American Society of Clinical Oncology 19: Abstract No. 310A, May 2000.
 66. The International Breast Cancer Study Group (Crivellari D., Pagani O., Goldhirsch A., Collins J., Schwarz M.A., et al : for the Anti-Cancer Council of Victoria). Central Nervous System Relapse in Patients treated with Epirubicin and Docetaxel as First Line Chemotherapy for Locally Advanced and/or Metastatic Breast Cancer. Proceedings of the American Society of Clinical Oncology 19: Abstract No. 553, May 2000.
 67. The International Breast Cancer Study Group (Castiglione-Gertsch M., Price K.N., Nasim L., Collins J., Schwarz M.A., et al: for the Anti-Cancer Council of Victoria). Is the Addition of Adjuvant Chemotherapy Always Necessary in Node Negative Post Menopausal Breast Cancer Patients Who Receive Tamoxifen? First Results of IBCSG Trial IX. Proceedings of the American Society of Clinical Oncology 19: Abstract No. 281, May 2000.
 68. The International Breast Cancer Study Group (Castiglione - Gertsch M., O'Neill A., Gelber R.D., Collins J., Schwarz M.A., et al : For the Anticancer Council of Victoria). Is the Addition of Adjuvant Chemotherapy Always Necessary In Node Negative Pre/Peri Menopausal Breast Cancer Patients Who Receive Goserelin? First Results of IBCSG Trial VIII Proceedings of the American Society of Clinical Oncology 21: Abstract No: 149, May 2002.
 69. The International Breast Cancer Study Group (Colleoni M., Zahrieh D., Nole F., Gelber R.D., Collins J., Schwarz M.A., et al : For the Anticancer Council of Victoria). Is Medial Breast Cancer Without Axillary Node Involvement Really Node Negative? Proceedings of the American Society of Clinical Oncology 21: Abstract No: 1696, May 2002.
 70. Haydon A.M., Schwarz M.A., Millar J.L., Farmer K.C., Cunningham I.G.E., and Shapiro J.D. Improved Management of Rectal Cancer in an Australian

Teaching Hospital. Medical Oncology Group of Australia National Conference: August 2002.

71. Loi S., Haydon A.M., Shapiro J.D., Schneider H., and Schwarz M.A. Review of Tumour Marker Usage in a Tertiary Public Hospital. Medical Oncology Group of Australia National Conference: August 2002.
72. The International Breast Cancer Study Group (Basser R., O'Neill A., Martinelli G., Green M., Schwarz M.A., et al: For the Cancer Council of Victoria). Randomized Trial Comparing Up-front, Multi-cycle Dose-intense Chemotherapy (CT) versus Standard Dose CT in Women with High Risk Stage 2 or 3 Breast Cancer (BC): First Results from IBCSG Trial 15 - 95. Proceedings of American Society of Clinical Oncology (ASCO) 22 : Abstract No: 20, May 2003.
73. The International breast Cancer Study Group (Pagani O., Gelber S., Simoncini E., Goldhirsch A., Schwarz M.A., et al : For the Cancer Council of Victoria). Randomized Comparison of Adjuvant Toremifene (TOR) versus Tamoxifen (TAM) for Postmenopausal Women with Node-Positive (N+), Estrogen Receptor Positive (ER+) Early Stage Breast Cancer. Proceedings of ASCO 22: Abstract No: 79, May 2003.
74. The International Breast Cancer Study Group (Colleoni, M., Li.S., Castiglione-Gertsch E., Gelber, R.D., Schwarz M.A., et al : For the Cancer Council of Victoria). Timing of Chemotherapy (CT) in Combination with Tamoxifen (TAM) in Postmenopausal Women with Breast Cancer; Role of Endocrine - Responsiveness of the Tumour. Proceedings of ASCO 22: Abstract No: 92, May 2003.
75. The International Breast Cancer Study Group (Bernhard J., Zahrieh D., Coates A.S., Gelber R.D., Forbes J.F., Schwarz M.A., et al : For the Cancer Council of Victoria). Quality adjusted Survival (QAS) in Postmenopausal Lymph Node-Negative Breast Cancer using Patient-Rated Health Status in a Q-TwiST Model. Proceedings of ASCO 22: Abstract No: 112, May 2003.
76. The International Breast Cancer Study Group (Viale G., Gelber R.D., Mastropasqua M.G., Maiorano E., Aldrighetto S., Price K.N., Castiglione-Gertsch M., Goldhirsch A., Schwarz M.A., et al : For the Cancer Council of Victoria). Chemo-Endocrine Effects of Adjuvant Therapies for Postmenopausal Node-Negative Breast Cancer according to ER, PgR and Her2 Assessed Centrally. Breast Cancer Research and Treatment 92 Suppl 1:516 - 17, (abstract 34), 2003.
77. The International Breast Cancer Study Group (Colleoni M., Gelber S., Snyder R., Coates A.S., Schwarz M.A., et al : For the Cancer Council of Victoria). Randomized Comparison of Adjuvant Tamoxifen versus no Hormonal Treatment for Premenopausal Women with Node-positive Early Stage Breast Cancer: First results of International Breast Cancer Study Group Trial 13 - 93. Proceedings of ASCO Vol 22, No 14S: Abstract No:532, July 2004.
78. International Breast Cancer Study Group (Holmberg S.B., Crivellari D., Zahrieh D., Forbes J.F., Schwarz M.A., et al : For the Cancer Council of Victoria). A Randomised Trial comparing Axillary Clearance versus no Axillary Clearance in Older Patients (> 60 years) with Breast Cancer: First results of International Breast Cancer Study Group Trial 10 - 93. Proceedings of ASCO Vol 22, No: 14S: Abstract No: 505, July 2004.

79. International Breast Cancer Study Group (Partridge A.H., Gelber S., Gelber R., Goldhirsch A., Winer E.P., Collins J., Snyder R.D., Schwarz M.A., et al: For the Cancer Council of Victoria): Delayed Premature Menopause Following Chemotherapy For Early Stage Breast Cancer : Long Term Results from IBCSG Trial V. Proceedings of AsCo Vol 23, No: 16S : Abstract No: 687, June 2005.
80. European Society of Organ Transplantation (E.S.O.T.). Incidence of Malignancies in Heart and/or Lung Transplant Recipients- an Australian Experience. Roithmaier S., Haydon A., Loi S., Esmore D., Griffiths A., Bergin P., Williams T., Schwarz M.A. Geneva, Proceedings of Conference: October 2005.
81. Incidence of Malignancies in Heart and/or Lung Transplant Recipients - An Australian Experience. Roithmaier S., Haydon A., Loi S., Esmore D., Griffiths A., Bergin P., Williams T., Schwarz M.A. Internal Medicine Journal; 36 (Suppl. 4): A141-162, 2006. (Awarded Best Poster at Annual Scientific Meeting of the Medical Oncology Group of Australia 9- 12th August 2006).
82. Acute Hypersensitivity Reactions to Chemotherapy: Give Consideration to the Vehicle. Larizza M., Dooley M.J., Haydon A., Schwarz M.A. Procedures of Clinical Oncology Society of Australia, Annual Scientific Meeting. November 2006.
83. Women's Knowledge of the Characteristics of their Newly-Diagnosed Invasive Breast Cancer. Australasian Menopause Society Meeting, Melbourne October 2008. Bell R.J., Lijovic M., Fradkin P., Bradbury J., La China M., Schwarz M.A., Wolfe R., Farrugia H., Davis S.
84. Knowledge of a Family History of Breast Cancer in Women Newly-diagnosed with Invasive Breast Cancer May Have Influenced Breast Screening Behaviour. Australasian Menopause Society Meeting, Melbourne October 2008. Lijovic M., Bell R., Fradkin P., Bradbury J., La China M., Schwarz M.A., Wolfe., Farrugia H., Davis S.
85. Hormone Therapy use at the Time of Diagnosis of Breast Cancer and Breast Cancer Characteristics. Australasian Menopause Society Meeting, Canberra 2009. Panjari M., Bell R., Lijovic M., La China M., Schwarz M.A., Fradkin P., Bradbury J., Farrugia H., Davis S.R.
86. Sexual Function after Breast Cancer. North American Menopause Society Meeting 2010. Bell R., Panjari M., La China M., Schwarz M.A., Fradkin P., Bradbury J., Davis S.
87. Health Related Quality of Life (QOL) Assessment in Stage 1 Seminomatous Germ Cell Tumour Patients Treated with Either Adjuvant Carboplatin Chemotherapy, Adjuvant Radiotherapy or High Intensity Chemotherapy. Lewin J., Haydon A., McKendrick J., Millar J., Schwarz M.A., Shapiro J., (Poster Presentation), 36th European Society of Medical Oncology Congress, Stockholm. September 23-27, 2011. European Journal of Cancer Vol 47, Supplement 1, September 2011, Page S526.
88. Incomplete Uptake and Diminished Adherence to Endocrine Therapy in Women with Hormone Receptor Positive Breast Cancer 4 Years from Diagnosis: An Australian Cohort Study. Bell R., Fradkin P., Schwarz M.A., Davis S.R. (Poster Presentation). San Antonio Breast Cancer Symposium, San Antonio, December 6-10, 2011.
89. Changes in Patterns of Use of Cigarettes and Alcohol in Women after a First

Diagnosis of Invasive Breast Cancer: a Cohort Study of Women from Victoria, Australia. (Oral Presentation). Bell R., Lijovic M., Fradkin P., Schwarz M.A., Davis S.R. 15th Australasian Menopause Society Congress, Brisbane, September 9-11, 2011. (Awarded the prize for the most meritorious contribution to the field of menopause based on a published or accepted paper in the previous 12 months).

90. Lewin J., Haydon A., McKendrick J., Millar J., Shapiro J., Schwarz M.A. Treatment Options for Stage I Seminoma Post Orchidectomy. Asia-Pacific Journal of Clinical Oncology 08/2012:8:53-53.
91. Bell R.J., Robinson P.J., Barallon R., Fradkin P., Schwarz M.A., Davis S.R. Lymphedema: Experience of a Cohort of Women with Breast Cancer Followed for 4 years after Diagnosis in Victoria, Australia. Victorian Integrated Cancer Services Inaugural State Conference, May 2013.
92. Bell R.J., Fradkin P., Parathithasan N., Robinson P.J., Schwarz M.A., Davis S.R. Gestational Breast Cancer and Pregnancy Following Treatment for Breast Cancer, in a Cohort of Women from Victoria, Australia, with a First Diagnosis of Invasive Breast Cancer. Australian Society for Psychosocial Obstetrics and Gynaecology Conference, Sydney, August 2013.
93. BETH: A Randomised Phase III Study Evaluating Adjuvant Bevacizumab added to Trastuzumab Chemotherapy for Treatment of Her 2+ Early Breast Cancer. Trio - 011 Trial Group. San Antonio Breast Cancer - American Association of Cancer Research Meeting, December 2013.
94. Duong B., Lee Y.C., Moore M., Ruben J., Gill S., Haydon A., Schwarz M.A., Freilich R., To Y., Dally M. Survival Outcomes of Patients with Glioblastoma Multiforme Treated to 60 Gy with or without Temozolomide at Three Melbourne Centres. Medical Oncology Group of Australia Annual Scientific Meeting: Hobart, August 5th - 7th 2015. Asia-Pacific Journal of Clinical Oncology 08/2015:11:53-53.